2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T471,Among 2 095 130 adolescent girls and women (median [IQR] age at diagnosis, 45 [41-48] years) who were followed up for 21 020 846 person-years, 16 385 breast cancer cases occurred. Ever use of any hormonal contraceptive was associated with increased breast cancer risk (HR, 1.24; 95% CI, 1.20-1.28), corresponding to 1 additional case per 7752 (95% CI, 5350-14 070) users, with both combined (HR, 1.12; 95% CI, 1.07-1.17) and progestin-only formulations (HR, 1.21; 95% CI, 1.17-1.25) being associated. Higher risk was associated with oral desogestrel-only formulations (HR, 1.18; 95% CI, 1.13-1.23) and oral desogestrel-combined formulations (HR, 1.19; 95% CI, 1.08-1.31), as well as implants containing etonogestrel, desogestrel's active metabolite (HR, 1.22; 95% CI, 1.11-1.35), compared to levonorgestrel-containing combined pills (HR, 1.09; 95% CI, 1.03-1.15) and levonorgestrel, 52 mg, intrauterine system (HR, 1.13; 95% CI, 1.09-1.18). No statistically significant increased risk was observed for medroxyprogesterone acetate injection, etonogestrel vaginal ring, or combined oral drospirenone, despite having many users.31:T95a,Hormonal contraceptives are widely used but how breast cancer risk differs by hormonal content remains unclear. To estimate the difference in breast cancer risk associated with different hormonal contraceptive formulations. This Swedish nationwide, population-based cohort study was conducted using linked national registers. All adolescent girls and women aged 13 to 49 years residing in Sweden as of January 1, 2006, with no history of breast cancer, ovarian cancer, cervical cancer, uterine cancer, bilateral oophorectomy, or infertility treatment were included and followed up from 2006 to 2019. Individuals were censored on meeting an exclusion criterion, reaching age 50 years, or study end, whichever occurred first. Data were analyzed from November 2023 to August 2025. Ever use and duration of use of hormonal contraceptives, categorized by hormone formulations and route of administration. Time-dependent Cox regression was used to estimate hazard ratios (HRs) with 95% CIs for incident cases of in situ and invasive breast cancer. Among 2 095 130 adolescent girls and women (median [IQR] age at diagnosis, 45 [41-48] years) who were followed up for 21 020 846 person-years, 16 385 breast cancer cases occurred. Ever use of any hormonal contraceptive was associated with increased breast cancer risk (HR, 1.24; 95% CI, 1.20-1.28), corresponding to 1 additional case per 7752 (95% CI, 5350-14 070) users, with both combined (HR, 1.12; 95% CI, 1.07-1.17) and progestin-only formulations (HR, 1.21; 95% CI, 1.17-1.25) being associated. Higher risk was associated with oral desogestrel-only formulations (HR, 1.18; 95% CI, 1.13-1.23) and oral desogestrel-combined formulations (HR, 1.19; 95% CI, 1.08-1.31), as well as implants containing etonogestrel, desogestrel's active metabolite (HR, 1.22; 95% CI, 1.11-1.35), compared to levonorgestrel-containing combined pills (HR, 1.09; 95% CI, 1.03-1.15) and levonorgestrel, 52 mg, intrauterine system (HR, 1.13; 95% CI, 1.09-1.18). No statistically significant increased risk was observed for medroxyprogesterone acetate injection, etonogestrel vaginal ring, or combined oral drospirenone, despite having many users. Findings of this cohort study highlight that breast cancer risk varies substantially by progestin content in hormonal contraceptives, providing valuable insights to support more informed contraceptive prescription.32:Te2f, Importance Hormonal contraceptives are widely used but how breast cancer risk differs by hormonal content remains unclear. Objective To estimate the difference in breast cancer risk associated with different hormonal contraceptive formulations. Design, Setting, and Participants This Swedish nationwide, population-based cohort study was conducted using linked national registers. All adolescent girls and women aged 13 to 49 years residing in Sweden as of January 1, 2006, with no history of breast cancer, ovarian cancer, cervical cancer, uterine cancer, bilateral oophorectomy, or infertility treatment were included and followed up from 2006 to 2019. Individuals were censored on meeting an exclusion criterion, reaching age 50 years, or study end, whichever occurred first. Data were analyzed from November 2023 to August 2025. Exposure Ever use and duration of use of hormonal contraceptives, categorized by hormone formulations and route of administration. Main Outcomes and Measures Time-dependent Cox regression was used to estimate hazard ratios (HRs) with 95% CIs for incident cases of in situ and invasive breast cancer. Results Among 2 095 130 adolescent girls and women (median [IQR] age at diagnosis, 45 [41-48] years) who were followed up for 21 020 846 person-years, 16 385 breast cancer cases occurred. Ever use of any hormonal contraceptive was associated with increased breast cancer risk (HR, 1.24; 95% CI, 1.20-1.28), corresponding to 1 additional case per 7752 (95% CI, 5350-14 070) users, with both combined (HR, 1.12; 95% CI, 1.07-1.17) and progestin-only formulations (HR, 1.21; 95% CI, 1.17-1.25) being associated. Higher risk was associated with oral desogestrel-only formulations (HR, 1.18; 95% CI, 1.13-1.23) and oral desogestrel-combined formulations (HR, 1.19; 95% CI, 1.08-1.31), as well as implants containing etonogestrel, desogestrel’s active metabolite (HR, 1.22; 95% CI, 1.11-1.35), compared to levonorgestrel-containing combined pills (HR, 1.09; 95% CI, 1.03-1.15) and levonorgestrel, 52 mg, intrauterine system (HR, 1.13; 95% CI, 1.09-1.18). No statistically significant increased risk was observed for medroxyprogesterone acetate injection, etonogestrel vaginal ring, or combined oral drospirenone, despite having many users. Conclusions and Relevance Findings of this cohort study highlight that breast cancer risk varies substantially by progestin content in hormonal contraceptives, providing valuable insights to support more informed contraceptive prescription. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Hormonal Contraceptive: modality Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Hormonal Contraceptive (modality). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/modality/Hormonal%20Contraceptive\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Modalities\",\"item\":\"https://www.reachrx.ai/hub/tag/modality\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Hormonal Contraceptive\",\"item\":\"https://www.reachrx.ai/hub/tag/modality/Hormonal%20Contraceptive\"}]}}"}}]],["$","$L2f",null,{"title":"Hormonal Contraceptive: Research & Clinical Takeaways","description":"Review evidence by treatment modality: Hormonal Contraceptive — concise summaries and practical next steps.","papers":[{"doi":"10.1093/humrep/deag101","pmid":"42381368","title":"Characterizing endometriosis and adenomyosis symptom clusters and their impact on quality of life in the\n All of Us\n Research Program","journal_title":"Human Reproduction","journal_issn":"0268-1161","published_at":"2026-07-01T00:00:00.000Z","url":"https://doi.org/10.1093/humrep/deag101","source_score":45,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-18T13:39:50.366Z","updated_at":"2026-07-18T13:39:50.366Z","tags":[{"paper_doi":"10.1093/humrep/deag101","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1093/humrep/deag101","tag_type":"category","value":"Obstetrics & Gynecology","value_numeric":null},{"paper_doi":"10.1093/humrep/deag101","tag_type":"condition","value":"Adenomyosis","value_numeric":null},{"paper_doi":"10.1093/humrep/deag101","tag_type":"condition","value":"Endometriosis","value_numeric":null},{"paper_doi":"10.1093/humrep/deag101","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1093/humrep/deag101","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1093/humrep/deag101","tag_type":"modality","value":"Hormonal Contraceptive","value_numeric":null},{"paper_doi":"10.1093/humrep/deag101","tag_type":"sample_size","value":"n=22438","value_numeric":22438},{"paper_doi":"10.1093/humrep/deag101","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1093/humrep/deag101","tag_type":"study_design","value":"Cross-Sectional Cohort Study","value_numeric":null},{"paper_doi":"10.1093/humrep/deag101","tag_type":"warning","value":"Latent class analysis is a data-driven method; the four-class solution is a model choice and alternative class numbers could yield different phenotypes.","value_numeric":null},{"paper_doi":"10.1093/humrep/deag101","tag_type":"warning","value":"Several co-authors have significant financial conflicts of interest related to endometriosis diagnostics and therapeutics (equity, patents, consulting). Results should be interpreted with this in mind.","value_numeric":null},{"paper_doi":"10.1093/humrep/deag101","tag_type":"warning","value":"The 'practice_changing' impact flag reflects the study's novel identification of a psychological/neurological phenotype and call for broader screening, but findings are observational and not yet validated in independent cohorts.","value_numeric":null}],"summaries":{"what_studied":"Using latent class analysis (LCA) on 22,438 women with endometriosis from the All of Us Research Program (May 2018–October 2023), this study identified distinct symptom phenotypes and evaluated how class membership predicts quality of life (QoL), including a subgroup analysis of adenomyosis co-occurrence in premenopausal women aged 18–45.","key_result":"Four symptom phenotypes emerged: a 'High Pain & Gastrointestinal with Mood Symptoms' cluster, a 'Predominantly Psychological/Neurological' cluster, and milder groups. Women with adenomyosis clustered into two high-pain classes with no minimal-symptom group, signaling higher overall burden. Membership in the high-burden class was linked to lower general health scores, reduced social satisfaction, and greater barriers to healthcare access.","limitations":"Cross-sectional design prevents causal inference on QoL. Diagnosis mix (surgical, clinical, and self-reported) may introduce misclassification. The 'Minimal Symptom Burden' class may reflect EHR under-documentation rather than true low symptom burden, and the US-only sample limits generalizability.","practice_takeaway":"Clinicians should screen young women presenting with non-classical symptoms—anxiety, migraine, or depression—for endometriosis, as a distinct psychological/neurological phenotype exists that may delay diagnosis. Interdisciplinary management addressing mental health and GI symptoms alongside pelvic pain is warranted for high-burden patients."}},{"doi":"10.1071/py25211","pmid":"42152183","title":"Women’s perspectives of community pharmacists’ resupplying and prescribing contraceptive methods","journal_title":"Australian Journal of Primary Health","journal_issn":"1448-7527","published_at":"2026-05-19T00:00:00.000Z","url":"https://doi.org/10.1071/py25211","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-27T15:43:09.257Z","updated_at":"2026-05-27T15:43:09.257Z","tags":[{"paper_doi":"10.1071/py25211","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1071/py25211","tag_type":"category","value":"Primary Health Care","value_numeric":null},{"paper_doi":"10.1071/py25211","tag_type":"condition","value":"Contraception","value_numeric":null},{"paper_doi":"10.1071/py25211","tag_type":"condition","value":"Emergency Contraception","value_numeric":null},{"paper_doi":"10.1071/py25211","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1071/py25211","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1071/py25211","tag_type":"modality","value":"Hormonal Contraceptive","value_numeric":null},{"paper_doi":"10.1071/py25211","tag_type":"sample_size","value":"n=22","value_numeric":22},{"paper_doi":"10.1071/py25211","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1071/py25211","tag_type":"study_design","value":"Qualitative Study","value_numeric":null},{"paper_doi":"10.1071/py25211","tag_type":"warning","value":"Study design is labelled as qualitative interviews; level of evidence assigned as 5 (expert opinion/qualitative) per standard hierarchy.","value_numeric":null},{"paper_doi":"10.1071/py25211","tag_type":"warning","value":"The sample (n=22) was recruited via convenience sampling from a narrow population (pharmacy visitors for emergency contraception or medical abortion), which may over-represent women already comfortable with pharmacy-based reproductive health services.","value_numeric":null},{"paper_doi":"10.1071/py25211","tag_type":"warning","value":"The study is qualitative and descriptive — no clinical outcomes, safety data, or comparators are reported.","value_numeric":null}],"summaries":{"what_studied":"This qualitative study explored Australian women's (n=22) acceptability of community pharmacists resupplying and prescribing hormonal contraceptives, using semi-structured interviews with women who had visited a pharmacy for emergency contraception or medical abortion medicines.","key_result":"Women broadly accepted pharmacist-led contraceptive resupply (citing convenience, cost, time savings, and improved access), but expressed low confidence in autonomous pharmacist prescribing — though confidence rose when pharmacists had received specific upskilling and training, particularly for first-time prescriptions.","limitations":"Very small convenience sample (n=22) limits generalisability; participants were recruited from a single access point (pharmacy visits for emergency contraception or medical abortion), which may skew perspectives; study is qualitative only, with no outcome or safety data.","practice_takeaway":"Pharmacists offering contraceptive resupply should communicate their training and qualifications clearly — women are more willing to accept pharmacist prescribing when they know pharmacists are appropriately upskilled. The GP relationship remains valued for initial prescribing, so collaborative models may be best received."}},{"doi":"10.1001/jamaoncol.2025.4480","pmid":"41165687","title":"Hormonal Contraceptive Formulations and Breast Cancer Risk in Adolescents and Premenopausal Women","journal_title":"JAMA Oncology","journal_issn":"2374-2437","published_at":"2025-10-30T00:00:00.000Z","url":"https://doi.org/10.1001/jamaoncol.2025.4480","source_score":661,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-12-19","doi":"10.1001/jamaoncol.2025.4480","days":"30","issn":"2374-2437","rank":"2","field":"Clinical Medicine","score":"661","category":"Oncology","categories":["Oncology"],"_categories":["Oncology"]},"pubmed":{"doi":"10.1001/jamaoncol.2025.4480","title":"Hormonal Contraceptive Formulations and Breast Cancer Risk in Adolescents and Premenopausal Women.","journal":"JAMA oncology","methods":"","results":"$30","abstract":"$31","keywords":[],"pubmed_id":"41165687","conclusions":"","publication_date":"2025-10-30T00:00:00"},"crossref":{"DOI":"10.1001/jamaoncol.2025.4480","URL":"https://doi.org/10.1001/jamaoncol.2025.4480","ISSN":["2374-2437"],"link":[{"URL":"https://jamanetwork.com/journals/jamaoncology/articlepdf/2840506/jamaoncology_hadizadeh_2025_oi_250066_1765564170.65132.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"1497","type":"journal-article","issue":"12","score":1,"title":["Hormonal Contraceptive Formulations and Breast Cancer Risk in Adolescents and Premenopausal Women"],"author":[{"given":"Fatemeh","family":"Hadizadeh","sequence":"first","affiliation":[{"name":"Department of Immunology, Genetics and Pathology, SciLifeLab, Uppsala University, Uppsala, Sweden"}]},{"given":"Ardita","family":"Koteci","sequence":"additional","affiliation":[{"name":"Department of Immunology, Genetics and Pathology, SciLifeLab, Uppsala University, Uppsala, Sweden"}]},{"given":"Torgny","family":"Karlsson","sequence":"additional","affiliation":[{"name":"Department of Immunology, Genetics and Pathology, SciLifeLab, Uppsala University, Uppsala, Sweden"}]},{"given":"Weronica E.","family":"Ek","sequence":"additional","affiliation":[{"name":"Department of Immunology, Genetics and Pathology, SciLifeLab, Uppsala University, Uppsala, Sweden"}]},{"given":"Åsa","family":"Johansson","sequence":"additional","affiliation":[{"name":"Department of Immunology, Genetics and Pathology, SciLifeLab, Uppsala University, Uppsala, Sweden"}]}],"issued":{"date-parts":[[2025,12,1]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":"11","created":{"date-time":"2025-10-30T15:31:38Z","timestamp":1761838298000,"date-parts":[[2025,10,30]]},"indexed":{"date-time":"2025-12-19T15:55:57Z","timestamp":1766159757013,"date-parts":[[2025,12,19]]},"subject":[],"abstract":"$32","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2840506"}},"subtitle":[],"deposited":{"date-time":"2025-12-18T16:00:53Z","timestamp":1766073653000,"date-parts":[[2025,12,18]]},"issn-type":[{"type":"print","value":"2374-2437"}],"published":{"date-parts":[[2025,12,1]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1016/S2468-2667(24)00156-7","key":"coi250066r1","year":"2024","issue":"8","author":"Sung","volume":"9","first-page":"e583","unstructured":null,"article-title":"Differences in cancer rates among adults born between 1920 and 1990 in the USA: an analysis of population-based cancer registry data.","journal-title":"Lancet Public Health","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamanetworkopen.2023.53331","key":"coi250066r2","year":"2024","issue":"1","author":"Xu","volume":"7","first-page":null,"unstructured":null,"article-title":"Breast cancer incidence among US women aged 20 to 49 years by race, stage, and hormone receptor status.","journal-title":"JAMA Netw Open","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41416-022-01704-x","key":"coi250066r3","year":"2022","issue":"10","author":"di Martino","volume":"126","first-page":"1374","unstructured":null,"article-title":"Incidence trends for twelve cancers in younger adults-a rapid review.","journal-title":"Br J Cancer","doi-asserted-by":"publisher"},{"DOI":"10.1016/S2214-109X(20)30215-1","key":"coi250066r4","year":"2020","issue":"8","author":"Heer","volume":"8","first-page":"e1027","unstructured":null,"article-title":"Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study.","journal-title":"Lancet Glob Health","doi-asserted-by":"publisher"},{"DOI":null,"key":"coi250066r5","year":"2025","issue":"1","author":"Siegel","volume":"75","first-page":"10","unstructured":null,"article-title":"Cancer statistics, 2025.","journal-title":"CA Cancer J Clin","doi-asserted-by":null},{"DOI":"10.1016/j.breast.2022.08.010","key":"coi250066r6","year":"2022","issue":null,"author":"Arnold","volume":"66","first-page":"15","unstructured":null,"article-title":"Current and future burden of breast cancer: global statistics for 2020 and 2040.","journal-title":"Breast","doi-asserted-by":"publisher"},{"DOI":"10.2147/BCTT.S390664","key":"coi250066r7","year":"2023","issue":null,"author":"Satish","volume":"15","first-page":"227","unstructured":null,"article-title":"Re-evaluating the association between hormonal contraception and breast cancer risk.","journal-title":"Breast Cancer (Dove Med Press)","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41586-023-06057-w","key":"coi250066r9","year":"2023","issue":"7967","author":"Lee","volume":"618","first-page":"1024","unstructured":null,"article-title":"ERa-associated translocations underlie oncogene amplifications in breast cancer.","journal-title":"Nature","doi-asserted-by":"publisher"},{"DOI":"10.1530/JME-20-0104","key":"coi250066r10","year":"2020","issue":"1","author":"Horwitz","volume":"65","first-page":"T49","unstructured":null,"article-title":"90 years of progesterone: progesterone and progesterone receptors in breast cancer: past, present, future.","journal-title":"J Mol Endocrinol","doi-asserted-by":"publisher"},{"DOI":"10.1590/1414-431x20175612","key":"coi250066r11","year":"2018","issue":"3","author":"Tian","volume":"51","first-page":"1","unstructured":null,"article-title":"Estrogen and progesterone promote breast cancer cell proliferation by inducing cyclin G1 expression.","journal-title":"Braz J Med Biol Res","doi-asserted-by":"publisher"},{"DOI":"10.15252/emmm.202114314","key":"coi250066r12","year":"2021","issue":"7","author":"Shamseddin","volume":"13","first-page":null,"unstructured":null,"article-title":"Contraceptive progestins with androgenic properties stimulate breast epithelial cell proliferation.","journal-title":"EMBO Mol Med","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jconrel.2022.03.057","key":"coi250066r13","year":"2022","issue":null,"author":"Gupta","volume":"345","first-page":"798","unstructured":null,"article-title":"Non-oral routes, novel formulations and devices of contraceptives: an update.","journal-title":"J Control Release","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(96)90806-5","key":"coi250066r14","year":"1996","issue":"9017","author":"Collaborative Group on Hormonal Factors in Breast Cancer","volume":"347","first-page":"1713","unstructured":null,"article-title":"Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53?297 women with breast cancer and 100?239 women without breast cancer from 54 epidemiological studies.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1158/1055-9965.EPI-10-0747","key":"coi250066r15","year":"2010","issue":"10","author":"Hunter","volume":"19","first-page":"2496","unstructured":null,"article-title":"Oral contraceptive use and breast cancer: a prospective study of young women.","journal-title":"Cancer Epidemiol Biomarkers Prev","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ajog.2021.12.022","key":"coi250066r16","year":"2022","issue":"6","author":"Burchardt","volume":"226","first-page":"821.e1","unstructured":null,"article-title":"Oral contraceptive use by formulation and breast cancer risk by subtype in the Nurses’ Health Study II: a prospective cohort study.","journal-title":"Am J Obstet Gynecol","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa013202","key":"coi250066r17","year":"2002","issue":"26","author":"Marchbanks","volume":"346","first-page":"2025","unstructured":null,"article-title":"Oral contraceptives and the risk of breast cancer.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1700732","key":"coi250066r18","year":"2017","issue":"23","author":"Mørch","volume":"377","first-page":"2228","unstructured":null,"article-title":"Contemporary hormonal contraception and the risk of breast cancer.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1371/journal.pmed.1004188","key":"coi250066r19","year":"2023","issue":"3","author":"Fitzpatrick","volume":"20","first-page":null,"unstructured":null,"article-title":"Combined and progestagen-only hormonal contraceptives and breast cancer risk: a UK nested case-control study and meta-analysis.","journal-title":"PLoS Med","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.lanepe.2022.100470","key":"coi250066r20","year":"2022","issue":null,"author":"Niemeyer Hultstrand","volume":"21","first-page":null,"unstructured":null,"article-title":"Hormonal contraception and risk of breast cancer and breast cancer in situ among Swedish women 15-34 years of age: a nationwide register-based study.","journal-title":"Lancet Reg Health Eur","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ajog.2024.05.011","key":"coi250066r21","year":"2024","issue":"4","author":"Yi","volume":"231","first-page":"450.e1","unstructured":null,"article-title":"Association of levonorgestrel-releasing intrauterine device with gynecologic and breast cancers: a national cohort study in Sweden.","journal-title":"Am J Obstet Gynecol","doi-asserted-by":"publisher"},{"DOI":"10.1093/jnci/djae282","key":"coi250066r22","year":"2025","issue":"5","author":"Tuesley","volume":"117","first-page":"1046","unstructured":null,"article-title":"Long-acting, progestin-based contraceptives and risk of breast, gynecological, and other cancers.","journal-title":"J Natl Cancer Inst","doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.2024.18575","key":"coi250066r23","year":"2024","issue":"18","author":"Mørch","volume":"332","first-page":"1578","unstructured":null,"article-title":"Breast cancer in users of levonorgestrel-releasing intrauterine systems.","journal-title":"JAMA","doi-asserted-by":"publisher"},{"DOI":"10.1097/AOG.0000000000005881","key":"coi250066r24","year":"2025","issue":"5","author":"Yuk","volume":"145","first-page":"523","unstructured":null,"article-title":"Association between levonorgestrel-releasing intrauterine system exposure duration and breast cancer incidence.","journal-title":"Obstet Gynecol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.maturitas.2003.09.020","key":"coi250066r25","year":"2003","issue":null,"author":"Druckmann","volume":"46","first-page":"S59","unstructured":null,"article-title":"Progestins and their effects on the breast.","journal-title":"Maturitas","doi-asserted-by":"publisher"},{"DOI":"10.1210/endrev/bnz001","key":"coi250066r26","year":"2020","issue":"2","author":"Trabert","volume":"41","first-page":"320","unstructured":null,"article-title":"Progesterone and breast cancer.","journal-title":"Endocr Rev","doi-asserted-by":"publisher"},{"DOI":"10.1186/s13643-016-0294-5","key":"coi250066r27","year":"2016","issue":"1","author":"Asi","volume":"5","first-page":"121","unstructured":null,"article-title":"Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis.","journal-title":"Syst Rev","doi-asserted-by":"publisher"},{"DOI":"10.1093/rheumatology/kead513","key":"coi250066r29","year":"2024","issue":"8","author":"Hadizadeh","volume":"63","first-page":"2101","unstructured":null,"article-title":"Effects of oral contraceptives and menopausal hormone therapy on the risk of rheumatoid arthritis: a prospective cohort study.","journal-title":"Rheumatology (Oxford)","doi-asserted-by":"publisher"},{"DOI":"10.1111/tri.13081","key":"coi250066r30","year":"2018","issue":"2","author":"Gleiss","volume":"31","first-page":"125","unstructured":null,"article-title":"An unjustified benefit: immortal time bias in the analysis of time-dependent events.","journal-title":"Transpl Int","doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.2020.9151","key":"coi250066r31","year":"2021","issue":"7","author":"Yadav","volume":"325","first-page":"686","unstructured":null,"article-title":"Immortal time bias in observational studies.","journal-title":"JAMA","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jcrc.2016.07.017","key":"coi250066r32","year":"2016","issue":null,"author":"Jones","volume":"36","first-page":"195","unstructured":null,"article-title":"Immortal time bias in observational studies of time-to-event outcomes.","journal-title":"J Crit Care","doi-asserted-by":"publisher"},{"DOI":"10.1016/0010-7824(82)90078-6","key":"coi250066r33","year":"1982","issue":"3","author":"Kuhl","volume":"26","first-page":"303","unstructured":null,"article-title":"Serum levels and pharmacokinetics of norethisterone after ingestion of lynestrenol: its relation to dose and stage of the menstrual cycle.","journal-title":"Contraception","doi-asserted-by":"publisher"},{"DOI":"10.1677/joe.0.0470251","key":"coi250066r34","year":"1970","issue":"2","author":"Mazaheri","volume":"47","first-page":"251","unstructured":null,"article-title":"Metabolism of lynestrenol to norethisterone by liver homogenate.","journal-title":"J Endocrinol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jclinepi.2009.03.012","key":"coi250066r35","year":"2010","issue":"1","author":"Austin","volume":"63","first-page":"46","unstructured":null,"article-title":"Absolute risk reductions and numbers needed to treat can be obtained from adjusted survival models for time-to-event outcomes.","journal-title":"J Clin Epidemiol","doi-asserted-by":"publisher"},{"DOI":"10.21037/atm.2018.01.36","key":"coi250066r36","year":"2018","issue":"7","author":"Zhang","volume":"6","first-page":"120","unstructured":null,"article-title":"Estimate risk difference and number needed to treat in survival analysis.","journal-title":"Ann Transl Med","doi-asserted-by":"publisher"},{"DOI":null,"key":"coi250066r37","year":"2008","issue":"6","author":"Maddox","volume":"33","first-page":"337","unstructured":null,"article-title":"Etonogestrel (Implanon), another treatment option for contraception.","journal-title":"Pharm Ther","doi-asserted-by":null},{"DOI":"10.1517/17425255.2013.844229","key":"coi250066r38","year":"2014","issue":"1","author":"Grandi","volume":"10","first-page":"1","unstructured":null,"article-title":"Pharmacokinetic evaluation of desogestrel as a female contraceptive.","journal-title":"Expert Opin Drug Metab Toxicol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.contraception.2011.12.015","key":"coi250066r39","year":"2012","issue":"3","author":"Hovanessian-Larsen","volume":"86","first-page":"238","unstructured":null,"article-title":"Lowering oral contraceptive norethindrone dose increases estrogen and progesterone receptor levels with no reduction in proliferation of breast epithelium: a randomized trial.","journal-title":"Contraception","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jsbmb.2023.106440","key":"coi250066r40","year":"2024","issue":null,"author":"Louw-du Toit","volume":"237","first-page":null,"unstructured":null,"article-title":"Progestins and breast cancer hallmarks: the role of the ERK1/2 and JNK pathways in estrogen receptor positive breast cancer cells.","journal-title":"J Steroid Biochem Mol Biol","doi-asserted-by":"publisher"},{"DOI":"10.1210/er.2003-0016","key":"coi250066r41","year":"2004","issue":"3","author":"Somboonporn","volume":"25","first-page":"374","unstructured":null,"article-title":"Testosterone effects on the breast: implications for testosterone therapy for women.","journal-title":"Endocr Rev","doi-asserted-by":"publisher"},{"DOI":"10.1530/JME-14-0030","key":"coi250066r42","year":"2014","issue":"3","author":"Fioretti","volume":"52","first-page":"R257","unstructured":null,"article-title":"Revising the role of the androgen receptor in breast cancer.","journal-title":"J Mol Endocrinol","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0303-7207(99)00109-4","key":"coi250066r43","year":"1999","issue":"1-2","author":"Bentel","volume":"154","first-page":"11","unstructured":null,"article-title":"Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells.","journal-title":"Mol Cell Endocrinol","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0039-128X(00)00119-7","key":"coi250066r44","year":"2000","issue":"10-11","author":"Kumar","volume":"65","first-page":"629","unstructured":null,"article-title":"Nestorone: a progestin with a unique pharmacological profile.","journal-title":"Steroids","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.contraception.2018.04.006","key":"coi250066r45","year":"2018","issue":"18","author":"Law","volume":"S0010-7824","first-page":"30142","unstructured":null,"article-title":"Twelve-month discontinuation rates of levonorgestrel intrauterine system 13.5 mg and subdermal etonogestrel implant in women aged 18-44: A retrospective claims database analysis.","journal-title":"Contraception","doi-asserted-by":"publisher"},{"DOI":"10.1186/s12905-022-01657-6","key":"coi250066r46","year":"2022","issue":"1","author":"Costescu","volume":"22","first-page":"82","unstructured":null,"article-title":"Discontinuation rates of intrauterine contraception due to unfavourable bleeding: a systematic review.","journal-title":"BMC Womens Health","doi-asserted-by":"publisher"},{"DOI":"10.1097/AOG.0b013e31821188ad","key":"coi250066r47","year":"2011","issue":"5","author":"Peipert","volume":"117","first-page":"1105","unstructured":null,"article-title":"Continuation and satisfaction of reversible contraception.","journal-title":"Obstet Gynecol","doi-asserted-by":"publisher"},{"DOI":"10.1016/S2214-109X(24)00560-6","key":"coi250066r48","year":"2025","issue":"4","author":"Cresswell","volume":"13","first-page":"e626","unstructured":null,"article-title":"Global and regional causes of maternal deaths 2009-20: a WHO systematic analysis.","journal-title":"Lancet Glob Health","doi-asserted-by":"publisher"},{"DOI":"10.1136/bmj.k3609","key":"coi250066r49","year":"2018","issue":null,"author":"Iversen","volume":"362","first-page":"k3609","unstructured":null,"article-title":"Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study.","journal-title":"BMJ","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.contraception.2020.06.008","key":"coi250066r50","year":"2020","issue":"3","author":"Iversen","volume":"102","first-page":"152","unstructured":null,"article-title":"Contemporary hormonal contraception and risk of endometrial cancer in women younger than age 50: a retrospective cohort study of Danish women.","journal-title":"Contraception","doi-asserted-by":"publisher"},{"DOI":null,"key":"coi250066r28","year":"2007","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"coi250066r8","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"World Family Planning 2022: meeting the changing needs for family planning: contraceptive use by age and method. United Nations. December 23, 2022. Accessed January 31, 2025. https://desapublications.un.org/publications/world-family-planning-2022-meeting-changing-needs-family-planning-contraceptive-use","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Oncology"],"published-print":{"date-parts":[[2025,12,1]]},"reference-count":50,"published-online":null,"references-count":50,"short-container-title":["JAMA Oncol"],"is-referenced-by-count":3},"unpaywall":{"doi":"10.1001/jamaoncol.2025.4480","is_oa":true,"title":"Hormonal Contraceptive Formulations and Breast Cancer Risk in Adolescents and Premenopausal Women","updated":"2025-12-10T03:52:38+00:00","published_date":"2025-10-30","best_oa_location":{"url":"https://jamanetwork.com/journals/jamaoncology/articlepdf/2840506/jamaoncology_hadizadeh_2025_oi_250066_1761596388.19423.pdf","pmh_id":null,"url_for_pdf":"https://jamanetwork.com/journals/jamaoncology/articlepdf/2840506/jamaoncology_hadizadeh_2025_oi_250066_1761596388.19423.pdf","url_for_landing_page":"https://doi.org/10.1001/jamaoncol.2025.4480"}}},"created_at":"2026-01-09T17:12:27.221Z","updated_at":"2026-01-18T22:40:12.285Z","tags":[{"paper_doi":"10.1001/jamaoncol.2025.4480","tag_type":"age_group","value":"adolescent","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2025.4480","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2025.4480","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2025.4480","tag_type":"condition","value":"Breast Cancer","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2025.4480","tag_type":"generic","value":"desogestrel","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2025.4480","tag_type":"generic","value":"drospirenone","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2025.4480","tag_type":"generic","value":"etonogestrel","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2025.4480","tag_type":"generic","value":"levonorgestrel","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2025.4480","tag_type":"generic","value":"medroxyprogesterone acetate","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2025.4480","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2025.4480","tag_type":"modality","value":"Hormonal Contraceptive","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2025.4480","tag_type":"sample_size","value":"n=2,095,130","value_numeric":2095130},{"paper_doi":"10.1001/jamaoncol.2025.4480","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2025.4480","tag_type":"study_design","value":"Cohort","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2025.4480","tag_type":"warning","value":"Duration-specific effects and dose information beyond the listed formulations are not provided in the excerpt.","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2025.4480","tag_type":"warning","value":"Formulation-specific estimates are summarized without full methodological context, limiting causal interpretation.","value_numeric":null},{"paper_doi":"10.1001/jamaoncol.2025.4480","tag_type":"warning","value":"The excerpt does not detail adjustment variables or confounders used in the Cox models.","value_numeric":null}],"summaries":{"what_studied":"A Swedish nationwide, population-based cohort of 2,095,130 adolescent girls and women aged 13–49 was followed from 2006 to 2019 to compare breast cancer incidence by hormonal contraceptive formulation and route using time-dependent Cox regression.","key_result":"Over 21,020,846 person-years, 16,385 breast cancers occurred. Ever use of any hormonal contraceptive was linked to higher risk (HR 1.24, 95% CI 1.20–1.28), ≈1 additional case per 7,752 users (95% CI 5,350–14,070); combined methods HR 1.12 (1.07–1.17) and progestin-only HR 1.21 (1.17–1.25); higher HRs with desogestrel-only oral (1.18, 1.13–1.23), desogestrel-combined oral (1.19, 1.08–1.31), and etonogestrel implant (1.22, 1.11–1.35); lower HRs with levonorgestrel-containing combined pills (1.09, 1.03–1.15) and levonorgestrel 52 mg intrauterine system (1.13, 1.09–1.18); no significant increase for medroxyprogesterone acetate injection, etonogestrel vaginal ring, or combined oral drospirenone.","practice_takeaway":"Breast cancer risk with hormonal contraception is small in absolute terms but varies by progestin; desogestrel/etonogestrel methods showed higher HRs than levonorgestrel pills or the levonorgestrel 52 mg IUS, while DMPA injection, the etonogestrel ring, and combined drospirenone showed no signal. Use the absolute risk (~1 extra case per 7,752 users) to guide counseling for adolescents and premenopausal women when choosing among formulations."}}],"initialOffset":3,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"modality","value":"Hormonal Contraceptive"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Modalities","href":"/hub/tag/modality"},{"name":"Hormonal Contraceptive"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"modality","hub_tag_value":"Hormonal Contraceptive"}}}]]

Papers